DLBCL Coverage Brought to You By

Tafasitamab Plus Lenalidomide With R-CHOP Improves Outcomes in High-Risk, Newly Diagnosed DLBCL

Matt Lunning, DO, FACP
Professor & James O. Armitage, MD, Chair of Hematologic Malignancies
Interim Chief of Hematology
Medical Director, Gene & Cellular Therapy
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE

Watch Matthew Lunning, DO, FACP, discuss the latest frontline advances in high-risk, newly diagnosed DLBCL, presented at the 2026 ASCO Annual Meeting. In this video, Dr. Lunning reviews the phase 3 frontMIND trial with progression-free survival and safety outcomes for tafasitamab plus lenalidomide in combination with R-CHOP.

View Transcript


© Amplity, Inc. All Rights Reserved. Privacy Policy